Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study
H Jourdain, A Di Meglio, I Mansouri, D Desplas, M Zureik, N Haddy · 2024
Read Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study by H Jourdain, A Di Meglio, I Mansouri, D Desplas, M Zureik, N Haddy (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11697054.txt.
Description
Jourdain and co-authors charted real-world use in 2024 of a targeted drug for breast cancer that has spread. The drug links a targeting protein to a cell-killing payload. It has been used in France since 2020 for cancers with high or low levels of that target and past care. The team used the French national health data system to find all who started the drug over three years.
The group held 5,890 patients in three bands by target level and line of care. Median age was near sixty. Brain spread was most common in the high-target group treated latest. Median survival was about thirty months in that band and about seventeen months in the low-target band. Rates of hospital stays for heart, lung, gut, and blood ills were much alike across bands.
Catalog record
| CREATOR | H Jourdain, A Di Meglio, I Mansouri, D Desplas, M Zureik, N Haddy |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |